Merck’s Potential Insomnia Treatment Proves Effective in Phase III Trials
Results from two Phase III trials for Merck’s insomnia drug suvorexant show it met all but one of its primary endpoints, setting Merck up for an NDA filing this year.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.